Login to Your Account



Psoriasis Survey Finds Market Robust, Room For Many Winners

By Randall Osborne


Monday, April 28, 2003

Familiarity may breed contempt in some settings, but in the prescription world it often means a leg up on competing drugs. Such appears to be the case with Enbrel (etanercept), Amgen Inc.'s rheumatoid arthritis treatment approved in 1998.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription